Protalix BioTherapeutics, Inc.
PLX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.70 | -0.10 | 0.09 | -0.01 |
| FCF Yield | 5.42% | -2.05% | -38.59% | -31.99% |
| EV / EBITDA | 18.73 | 9.60 | -7.68 | -1.65 |
| Quality | ||||
| ROIC | 5.61% | 16.38% | -55.13% | -47.69% |
| Gross Margin | 54.46% | 64.91% | 58.87% | 57.37% |
| Cash Conversion Ratio | 2.96 | -0.16 | 1.67 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.88% | 19.53% | -8.85% | -11.16% |
| Free Cash Flow Growth | 399.64% | 90.37% | -118.22% | 56.12% |
| Safety | ||||
| Net Debt / EBITDA | -2.18 | 0.31 | -1.52 | 0.29 |
| Interest Coverage | 3.69 | 3.29 | -5.15 | -2.72 |
| Efficiency | ||||
| Inventory Turnover | 1.14 | 1.21 | 1.17 | 0.91 |
| Cash Conversion Cycle | 270.68 | 263.24 | 238.99 | 277.63 |